Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Bioepis And C-Bridge Capital Deal Eyes Up ‘Next-Generation’ Biosimilars In China

Executive Summary

Partnership, which names Lucentis, Soliris and Herceptin biosimilars as being under its remit, brings together Samsung Bioepis’ “proven agile biologics development platform and C-Bridge’s strong capital resource and China healthcare expertise,” according to the Korean firm.

You may also be interested in...

Samsung Bioepis Can Begin Eculizumab Trial In China

Samsung Bioepis and partner AffaMed Therapeutics have received an approval from the Chinese authorities to conduct a Phase III study for their eculizumab biosimilar rival to Soliris at Chinese sites. Meanwhile, Samsung Bioepis has also just completed a global Phase III trial for its ranibizumab version of Lucentis.

AffaMed And Samsung Bioepis Get Chinese Nod For Trastuzumab Trial

CBC Group’s AffaMed and partner Samsung Bioepis have received clearance from China’s NMPA to proceed with a Phase III trial in China for biosimilar trastuzumab.

Samsung Bioepis Adds To Biogen Collaboration

Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts